Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K for the 4S Group Reduced Coronary Events in Simvastatin-Treated.

Slides:

Advertisements

Similar presentations

The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.

Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Factors associated with prediabetes in adult children of patients with premature coronary heart disease; the study of families of patients with premature.

Lipid Disorders and Management in Diabetes

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The efFects of Pharmacological management of lipids in patients with CKD Andrew Monson FY1 18/9/14.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.

Introduction To The Alphabet Strategy And Evidence Based Medicine.

Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.

TC LDL- C HDL- C Nonfatal MI/CHD death CHD death All- cause mortality *As compared to placebo. † P= CARE: Effect of Lipid Lowering on Lipid Values.

TM © 1999 Professional Postgraduate Services ® S: Total Mortality Reduction in a Subgroup of Patients With Diabetes Proportion.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

Role of Rosuvastatin in the Treatment of Dyslipidemia

Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

Cholesterol-Lowering Therapy in Women and Elderly Patients with Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival.

Modern Management of Cholesterol in the High-Risk Patient.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

OVERALL SURVIVAL Adapted from Scandinavian Simvastatin Survival Study Group Lancet 1994;344: % of patients alive Simvastatin (n=2221)

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

Diabetes... Common and underdiagnosed Causes macro- and microvascular events Reduces duration and quality of life.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

4S: Scandinavian Simvastatin Survival Study

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Search strategy and results Amir Kashani, et al. Circulation. 2006;114:

ALLHAT ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status.

Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.

The Anglo Scandinavian Cardiac Outcomes Trial

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Scandinavian Simvastatin Survival Study (4S)

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Baseline characteristics of HPS participants by prior diabetes

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The results of the SHARP trial

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Description of studies for pooled analyses

LRC-CPPT and MRFIT Content Points:

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Goals & Guidelines A summary of international guidelines for CHD

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

The results of the SHARP trial

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Prevalence of diabetes (DM) after pancreaticoduodenectomy for PDAC

Presentation transcript:

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K for the 4S Group Reduced Coronary Events in Simvastatin-Treated Subjects with CHD and Diabetes or Impaired Fasting Glucose: Subgroup Analyses in the Scandinavian Simvastatin Survival Study Arch Intern Med 1999;159:

Expanded 4S Diabetes Analysis Diabetes Mellitus by HistoryDiabetes Mellitus by History –202 Subjects (Original 4S Diabetes Subgroup) FG > 126 mg/dl, but No History of DiabetesFG > 126 mg/dl, but No History of Diabetes –281 Subjects Impaired Fasting Glucose (FG mg/dl)Impaired Fasting Glucose (FG mg/dl) –678 Subjects Normal (FG < 110 mg/dl)Normal (FG < 110 mg/dl) –3,237 Subjects Haffner SM, et al. Arch Intern Med 1999;159:

Rationale & Goals Rationale New ADA Diagnostic Criteria for DM (FG > 126 mg/dl)New ADA Diagnostic Criteria for DM (FG > 126 mg/dl) New Category of IFG (FG mg/dl)New Category of IFG (FG mg/dl)Goals Confirm previous dataConfirm previous data Perform analysis of 4S subjects with IFGPerform analysis of 4S subjects with IFG Haffner SM, et al. Arch Intern Med 1999;159:

Baseline Characteristics NormalIFGDM-FGDM - Hx n Age Male (%) SBP Tot-C LDL-C HDL-C TG FG Haffner SM, et al. Arch Intern Med 1999;159:

Percent Change in Lipids and Lipoproteins in 4S Haffner SM, et al. Arch Intern Med 1999;159:

Incidence of Major CHD Events by Glucose Status in the 4S Placebo Group NFG(n=1631)IFG(n=335)DM-FG(n=135)DM-history(n=97) Baseline Glucose Status Haffner SM, et al. Arch Intern Med 1999;159:

4S ~ Major Coronary Heart Disease Events RR = p value = < n = 1631/ / /251 Haffner SM, et al. Arch Intern Med 1999;159:

4S & Revascularizations RR = p value = < n = 1631/ / /251 Haffner SM, et al. Arch Intern Med 1999;159:

4S ~ Total Mortality RR = p value = n = 1631/ / /251 Haffner SM, et al. Arch Intern Med 1999;159:

IFG Subjects (n=678) Relative Risk MCE Revascularization Tot Mortality CHD Mortality p=0.003 p=0.009 p=0.02 p= Haffner SM, et al. Arch Intern Med 1999;159:

Diabetic Subjects (n=483) Relative Risk MCE Revascularization Tot Mortality CHD Mortality p=0.001 p=0.005 p=0.34 p= Haffner SM, et al. Arch Intern Med 1999;159:

Major CHD Events Major CHD Events NFG Simvastatin NFG Placebo IFG Simvastatin IFG Placebo DM Simvastatin DM Placebo Arch Intern Med 1999;159:

Effects of Simvastatin on Major Coronary Events by Glucose Status Stratified by Level of Lipid Parameters Arch Intern Med 1999;159:

Absolute and Relative Risk Benefit of Simvastatin Therapy by Glucose Status for Major Coronary Events NFGIFGDM Simvastatin group, No. (%) 299/1606 (18.6) 67/343 (19.5) 59/251 (23.5) Placebo group, No. (%) 428/1631 (26.2) 102/335 (30.5) 87/232 (37.5) Relative risk P relative risk< Absolute benefit (Kaplan-Meier year 6 estimate) 8.02/100 cases 12.11/100 cases 13.85/100 cases 6 estimate) 8.02/100 cases 12.11/100 cases 13.85/100 cases Number needed to treat1287 Haffner SM, et al. Arch Intern Med 1999;159:

Summary - Diabetes Mellitus Higher event rate in diabetes group, by history, compared to other groupsHigher event rate in diabetes group, by history, compared to other groups In combined DM group (by history and fasting glucose):In combined DM group (by history and fasting glucose): –Major Coronary Events were reduced by 42% (p=0.001) –Revascularizations were reduced by 48% (p=0.005) Total and coronary mortality were reduced, but reductions not significant due to small sample sizeTotal and coronary mortality were reduced, but reductions not significant due to small sample size Haffner SM, et al. Arch Intern Med 1999;159:

Summary - Impaired Fasting Glucose Reduced total mortality by 43% (p=0.02)Reduced total mortality by 43% (p=0.02) Reduced coronary mortality by 55% (p=0.007)Reduced coronary mortality by 55% (p=0.007) Reduced major coronary events by 38% (p=0.003)Reduced major coronary events by 38% (p=0.003) Reduced the need for revascularization procedures by 43% (p=0.009)Reduced the need for revascularization procedures by 43% (p=0.009) Haffner SM, et al. Arch Intern Med 1999;159:

ConclusionsConclusions This analysis confirms and extends the benefit of cholesterol lowering with simvastatin in an expanded cohort of patients with diabetes and overt CHDThis analysis confirms and extends the benefit of cholesterol lowering with simvastatin in an expanded cohort of patients with diabetes and overt CHD CHD patients with impaired fasting glucose (FG 110 to 125 mg/dL) benefit from treatment with simvastatin by significant & substantial reductions in total and coronary mortality, major CHD events and revascularizations.CHD patients with impaired fasting glucose (FG 110 to 125 mg/dL) benefit from treatment with simvastatin by significant & substantial reductions in total and coronary mortality, major CHD events and revascularizations. Haffner SM, et al. Arch Intern Med 1999;159: